Aclarion (ACON) Conference Call Summary Company Overview - Aclarion focuses on addressing chronic low back pain, a significant healthcare issue in the United States and globally [1] - The company has a strong financial position with nearly $14.6 million in cash, zero debt, and is fully compliant with NASDAQ requirements [2][26] Industry Context - Chronic low back pain affects approximately 266 million people worldwide, making it the leading cost ailment in healthcare [3][4] - In the U.S., there are 635,000 spinal fusion surgeries annually, with high costs averaging $58,000 for one-level and $71,000 for two-level procedures [4] - Surgical success rates are low, with only 48-54% achieving success, and 80% of patients experiencing discomfort post-surgery [4][5] Market Opportunity - The initial addressable market for Aclarion's product, NOSI Scan, is estimated at $6.03 billion based on the fusion and disc replacement market [6] - The potential revenue increases significantly when considering other spine procedures and chiropractic care [7] Product and Technology - NOSI Scan utilizes spectroscopy to measure pain biomarkers and structural integrity within spinal discs, providing a non-invasive diagnostic alternative to traditional methods [9][12] - The technology is patented with over 40 patents worldwide, covering various aspects of the product and its application [13] Clinical Evidence and Trials - Aclarion is conducting a national randomized controlled trial called CLARITY, which is fully funded at $4.6 million, to provide robust evidence for the efficacy of NOSI Scan [3][16] - Previous studies indicate that 85% of patients improved when treated based on NOSI Scan results, compared to 63% without treatment [15][16] Regulatory and Market Strategy - The company has secured payer approvals in the UK, covering over 5.2 million people, and is working to expand its market presence [17][19] - Aclarion aims to transition its CPT codes from category three to category one to facilitate reimbursement in the U.S. [20] Management Team - The management team has extensive experience in healthcare and technology, with zero turnover since the IPO [21][24] - Key team members include a board-certified neurosurgeon and executives with backgrounds in major healthcare companies [22][24] Challenges and Future Outlook - The introduction of new technology into the payer community is challenging and requires tactical efforts to gain acceptance [34] - Aclarion is focused on building KOL advocacy and societal support to overcome reimbursement barriers [33][34] Key Takeaways - Aclarion is positioned to address a significant healthcare issue with a unique, non-invasive diagnostic tool that has strong market potential [25] - The company is well-funded and has a clear roadmap for expanding its commercial footprint and driving payer acceptance [26][27]

Core Insights - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][4] - The company will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025, highlighting recent initiatives aimed at enhancing value [2][1] - Aclarion has released an updated investor presentation available on its website [3] Company Overview - Aclarion leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments for chronic low back pain [4] - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4] - Nociscan utilizes cloud technology to analyze MRS data from MRI machines, extracting chemical biomarkers associated with disc pain to provide insights for treatment optimization [4]

Core Insights - Aclarion, Inc. has published a peer-reviewed article demonstrating the cost-effectiveness of its Nociscan solution compared to provocative discography for identifying chronic low back pain surgery candidates [1][2] - The study indicates that Nociscan saves approximately $1,712 per patient and improves surgical success rates by 10% [5] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to help physicians differentiate between painful and non-painful discs [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist in diagnosing disc-related pain [4] Industry Context - Chronic low back pain affects around 266 million people globally, highlighting the significant healthcare challenge it presents [2] - The publication in ClinicoEconomics and Outcomes Research emphasizes the need for more evidence on clinical and economic improvements in healthcare diagnostics [1]

Company Overview - Aclarion, Inc. is a healthcare technology company focused on leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying the location of chronic low back pain [1][3] - The company is addressing the chronic low back pain market with its product Nociscan, which is the first evidence-supported SaaS platform designed to noninvasively help physicians distinguish between painful and non-painful discs in the lumbar spine [3] Product Details - Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [3] - The platform receives MRS data from MRI machines and processes it in the cloud to extract and quantify chemical biomarkers associated with disc pain [3] - Nociscan provides critical insights into the location of a patient's low back pain, enabling physicians to optimize treatment strategies [3] Upcoming Events - Aclarion will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025, at 12:30 PM ET, hosted by CEO Brent Ness [1][2] - The presentation will be accessible via a live webcast, and 1x1 investor meetings can be scheduled at the conference venue [2]

Cash and Cash Equivalents - As of December 31, 2024, the company had cash and restricted cash totaling $463,661, primarily invested in demand deposit accounts and money market funds[450] - The company considers all highly liquid debt instruments purchased with a maturity of three months or less as cash equivalents[450] Investment Objectives and Risks - The primary objectives of the company's investing activities are capital preservation, meeting liquidity needs, and generating interest income while maintaining the safety of principal[450] - The company's cash equivalents are subject to market risk due to changes in interest rates, which may adversely affect the market value of fixed-rate securities[451] - Future investment income may fall short of expectations due to changes in interest rates, potentially leading to losses in principal if securities are sold at a decline in market value[451]

Core Insights - Aclarion, Inc. has expanded its Nociscan product availability to Santa Monica, enhancing access to its diagnostic services for chronic low back pain [3][4] - The Medical Imaging Center of Southern California (MICSC) is now offering Nociscan, which was previously exclusive to its Beverly Hills location, thereby replicating the benefits for patients and physicians in a new market [4] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in diagnosing pain sources [3][9] - Nociscan is the first evidence-supported SaaS platform that noninvasively helps distinguish between painful and nonpainful discs in the lumbar spine, providing critical insights when used alongside other diagnostic tools [7][9] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge it presents [5] - Los Angeles, with a population exceeding 3.8 million, is a strategically important market for Aclarion, being the most populous city in California and the second-most populous in the United States [5][6]

Core Insights - Aclarion, Inc. has expanded the availability of its Nociscan product to Santa Monica, enhancing access to its MRI and diagnostic imaging services for chronic low back pain [1][2] - Nociscan is the first evidence-supported SaaS platform that helps physicians differentiate between painful and nonpainful discs in the lumbar spine, utilizing biomarkers and AI algorithms [4][6] - Chronic low back pain affects approximately 266 million people globally, highlighting the significant market potential for Aclarion's solutions [3] Company Overview - Aclarion, Inc. leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments, specifically targeting the chronic low back pain market with its Nociscan platform [6] - The company’s Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][6] Market Context - Los Angeles, with a population exceeding 3.8 million, represents a strategically important market for Aclarion, alongside New York City [3] - The expansion of Nociscan services to Santa Monica is part of MICSC's commitment to adopting innovative solutions that enhance patient care and physician support [2]

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market "The Company is accelerating across all areas of execution," said Brent Ness, CEO of Aclarion. "In addition to strong momentum enrolling CLARITY sites, we've made meaningful commercial progress. We're also driving adoption in London, where we recently secured payer approvals and have built deep support among referring physicians and radiologists. Beyond London, we're ...

Core Insights - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][3] - The company plans to file its 10K report by the end of March, which will include a more detailed corporate update [2] Company Overview - Aclarion leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [3] - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [3] - Nociscan processes MRS data from MRI machines to extract and quantify chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [3]

Core Insights - Aclarion, Inc. is expanding the access of its Nociscan technology across multiple sites in New York and New Jersey to address the growing demand for chronic low back pain solutions [1][2] - The expansion is supported by enhanced remote operations capabilities and increased availability of Magnetic Resonance Spectroscopy (MRS) within RadNet [1][2] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary AI algorithms to assist physicians in identifying chronic low back pain locations [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][5] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge [4] - The Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][5] Strategic Partnerships - Lenox Hill Radiology operates 79 locations in New York and has adopted Nociscan to enhance access for leading spine physicians [2][3] - New Jersey Imaging Network, with 33 locations, was the first in NJ to adopt Nociscan, facilitating support for local and out-of-market referrals [3]